FDA’s priority vouchers promise benefits, but may come at a cost
BY Blinn E. Combs, Esq. and Michael R. Alexander, Esq., Brown & Fortunato, P.C. On June 17, 2025, a little over two months after initiating large-scale layoffs at the agency, the federal Food and Drug Administration (“FDA”) announced a new Commissioner’s National Priority Voucher (“CNPV”) program. The CNPV aimed to give voucher recipients the opportunity to shorten new drug approval timelines from 10-12 months down to 1-2 months. The program aims to address four...











